Skip to main content
logo
Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
17.26
+0.20 (1.17%)
Sep 4, 2026, 4:00 PM EDT - Market closed

Trevi Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
2,4591,6053688611620
Market Cap Growth
182.43%336.04%330.28%-26.01%472.04%-54.55%
Enterprise Value
2,1411,411304-216
Last Close Price
17.2612.524.121.341.930.78

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PB Ratio
7.658.763.701.041.081.18
P/TBV Ratio
7.658.763.701.041.081.18

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.000.000.010.020.090.86
Net Debt / Equity Ratio
-0.99-1.02-1.07-0.99-1.04-1.29
Net Debt / EBITDA Ratio
5.363.812.082.423.730.68
Net Debt / FCF Ratio
6.024.452.782.563.930.76
Quick Ratio
36.6819.4110.2914.338.992.90
Current Ratio
37.2819.6610.4115.039.152.98
Return on Equity (ROE)
-19.66%-30.23%-52.59%-30.59%-46.82%-153.03%
Return on Assets (ROA)
-13.81%-20.26%-32.15%-19.96%-23.15%-47.42%
Return on Capital Employed (ROCE)
-18.50%-26.90%-51.30%-40.60%-27.30%-126.10%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-2.08%-2.66%-13.01%-33.97%-25.21%-167.88%
FCF Yield
-2.15%-2.62%-10.40%-37.22%-24.50%-143.18%
Buyback Yield / Dilution
-26.95%-32.14%-2.97%-53.44%-182.56%-26.48%
SEC Filings: 10-K · 10-Q